The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Survival and transformation of follicular lymphoma: a Finnish nationwide population-based study
Sirpa Leppa, MD, PhD, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, outlines the results of an epidemiological study conducted in Finland which analyzed the overall survival (OS) and risk of transformation to large B-cell lymphoma (LBCL) in patients diagnosed with follicular lymphoma (FL). Overall, it was found that transformation was associated with an increased risk of death and shorter OS. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Incyte: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Research Funding; Gilead Sciences: Consultancy, Honoraria; BMS: Consultancy, Research Funding; Bayer: Research Funding; Orion Pharma: Consultancy; Pfizer: Consultancy; Beigene: Consultancy; Genmab: Research Funding; Nordic Nanovector: Research Funding.
